Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
Deng, T.; Zeng, G.
JAMA Oncology 6(7): 1113-1114
2020
ISSN/ISBN: 2374-2437
PMID: 32352500
DOI: 10.1001/jamaoncol.2020.0625
Accession: 070074293
PDF emailed within 0-6 h: $19.90
Related References
Duan, J.; Cui, L.; Zhao, X.; Bai, H.; Cai, S.; Wang, G.; Zhao, Z.; Zhao, J.; Chen, S.; Song, J.; Qi, C.; Wang, Q.; Huang, M.; Zhang, Y.; Huang, D.; Bai, Y.; Sun, F.; Lee, J.Jack.; Wang, Z.; Wang, J. 2020: Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis JAMA Oncology 6(3): 375-384Ghiorghiu, S.; Mukhopadhyay, P.; Massacesi, C. 2020: Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer JAMA Oncology 6(7): 1115-1116
Bomze, D.; Azoulay, D.; Meirson, T. 2020: Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer JAMA Oncology 6(7): 1114-1115
Wang, T.; Lee, S.; Feldman, G.M. 2020: Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer JAMA Oncology 6(7): 1115
Sun, X.; Roudi, R.; Dai, T.; Chen, S.; Fan, B.; Li, H.; Zhou, Y.; Zhou, M.; Zhu, B.; Yin, C.; Li, B.; Li, X. 2019: Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis Bmc Cancer 19(1): 558
Lazarus, G.; Audrey, J.; Iskandar, A.William.Brian. 2019: Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review Oncology Reviews 13(2): 425
Fukuda, M.; Yamaguchi, H.; Mukae, H.; Ashizawa, K. 2018: Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer Journal of Thoracic Disease 10(Suppl. 33): S4082-S4084
Choi, F.D.; Kraus, C.N.; Elsensohn, A.N.; Carley, S.K.; Lehmer, L.M.; Nguyen, R.T.; Linden, K.G.; Shiu, J. 2020: Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review Journal of the American Academy of Dermatology 82(2): 440-459
Remon, J.; Chaput, N.; Planchard, D. 2016: Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer Current Opinion in Oncology 28(2): 122-129
Khunger, M.; Rakshit, S.; Pasupuleti, V.; Hernandez, A.V.; Mazzone, P.; Stevenson, J.; Pennell, N.A.; Velcheti, V. 2017: Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials Chest 152(2): 271-281
Gao, Y.; Li, S.; Xu, D.; Chen, S.; Cai, Y.; Jiang, W.; Zhang, X.; Sun, J.; Wang, K.; Chang, B.; Wang, F.; Hong, M. 2017: Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma Chinese Journal of Cancer 36(1): 61
Rivera, N.; Boada, A.; Bielsa, M.Isabel.; Fernández-Figueras, M.Teresa.; Carcereny, E.; Moran, M.Teresa.; Ferrándiz, C. 2017: Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer JAMA Dermatology 153(11): 1162-1165
Cortellini, A.; Bersanelli, M.; Santini, D.; Buti, S.; Tiseo, M.; Cannita, K.; Perrone, F.; Giusti, R.; De Tursi, M.; Zoratto, F.; Marconcini, R.; Russano, M.; Zeppola, T.; Anesi, C.; Filetti, M.; Marchetti, P.; Botticelli, A.; Gelibter, A.; De Galitiis, F.; Vitale, M.Giuseppa.; Rastelli, F.; Tudini, M.; Silva, R.Rita.; Atzori, F.; Chiari, R.; Ricciuti, B.; De Giglio, A.; Migliorino, M.Rita.; Mallardo, D.; Vanella, V.; Mosillo, C.; Bracarda, S.; Rinaldi, S.; Berardi, R.; Natoli, C.; Ficorella, C.; Porzio, G.; Ascierto, P.A. 2020: Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events European Journal of Cancer 128: 17-26
Zhao, J.; Huang, J. 2020: Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1 Chinese Medical Journal 133(7): 853-862
Pattanaik, S.; Dey, S.; Jaiswal, N.; Rohilla, R.; Singh, S.Kumar.; Mandal, A.Kumar.; Mavuduru, R.Suryanarayan. 2019: Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis Indian Journal of Urology: Iju: Journal of the Urological Society of India 35(2): 101-115